CD276 (human) AlphaLISA Detection Kit, 500 assay points

Formats:

• Our 100 assay point kit allows you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
• Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
• Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features:

• No-wash steps, no separation steps
• ELISA alternative technology
• Sensitive detection
• Broad sample compatibility
• Small sample volume
• Results in less than 3 hours
• Half the time of an ELISA assay

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

CD276 (Cluster of Differentiation 276, or B7-H3) is a type I transmembrane protein belonging to the B7 family of co-stimulatory proteins (e.g., B7-1, or CD80). It signals through CD28 family molecules such as CD28 and CTLA4. It is expressed ubiquitously, such as dendritic cells derived from monocytes, epithelial cells of sinonasal tissue, extravillous trophoblast cells and Hofbauer cells of the placenta. It is an immune checkpoint molecule, involved in the regulation of T-cell-mediated immune response. It is expressed by some solid tumours, as a biomarker for detection of neuroblastoma cells and is the target of anticancer therapy.